Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–7 of 7 results
Advanced filters: Author: "Josep Tabernero" Clear advanced filters

  • The results of a number of studies have demonstrated the promise of adding intrahepatic arterial selective internal radiotherapy (SIRT) to chemotherapy for patients with liver metastases from colorectal cancer; however, the frequent progression of extrahepatic metastases observed in patients treated with SIRT in the SIRFLOX trial call the potential overall benefit of this approach into question.

    • Josep Tabernero
    • Ramon Salazar
    News & Views
    Nature Reviews Clinical Oncology
    Volume: 13, P: 467-468

  • Patients with c-MET-expressing colorectal or gastrointestinal cancers generally have worse outcomes than those of patients whose tumours have low levels of, or absent c-MET expression. However, c-MET targeted agents have, thus far, failed to show clinical efficacy. In this Review, the authors describe the opportunities and challenges created by the clinical implementation of c-MET targeted therapies.

    • Conor A. Bradley
    • Manuel Salto-Tellez
    • Sandra Van Schaeybroeck
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 14, P: 562-576

  • This Perspectives article describes how phase I trials assessing the efficacy of targeted therapies should examine not only safety and toxicity, but also the appropriate patient population. Based on the experience of their own academic institution, Rodón and colleagues explain how to build a pre-screening programme in early drug development.

    • Jordi Rodón
    • Cristina Saura
    • Josep Tabernero
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 9, P: 359-366

  • Circulating blood biomarkers are promising non-invasive real-time surrogates for tumour tissue-based biomarkers, and in breast cancer they have been used as tools for diagnosis, prognostication, prediction, monitoring of therapeutic response, and resistance. This Review outlines the techniques, challenges and possibilities of this promising area.

    • Leticia De Mattos-Arruda
    • Javier Cortes
    • Joan Seoane
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 377-389

  • Biomarkers that predict a patient's responsiveness to anticancer therapies are of increasing importance during drug development and in clinical trials, as well as in the clinic. In this Review, the major challenges to biomarker development and standardization are discussed, and the considerations for validation of the pre-analytical, analytical and post-analytical protocols involved in biomarker assays are highlighted.

    • Armand de Gramont
    • Sarah Watson
    • Stanley R. Hamilton
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 12, P: 197-212

  • Agents targeting the PI3K/AKT/mTOR pathway have been shown to be safe and effective in treating a number of tumour types. This Review outlines the background to these inhibitors and discusses the second-generation inhibitors of this pathway. The authors propose that the way forward for the development of inhibitors of the PI3K/AKT/mTOR pathway might be a systems biology approach and biomarker-driven studies.

    • Jordi Rodon
    • Rodrigo Dienstmann
    • Josep Tabernero
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 10, P: 143-153